Surmodics Inc. Announces Multiple Corporate Events
| Field | Detail |
|---|---|
| Company | Surmodics Inc |
| Form Type | 8-K |
| Filed Date | Nov 19, 2025 |
| Risk Level | high |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.05, $43.00, $25.0 million |
| Sentiment | mixed |
Sentiment: mixed
Topics: termination-agreement, asset-disposition, delisting-notice, change-of-control
Related Tickers: SRDX
TL;DR
Surmodics just terminated a big deal, sold assets, and might be delisted. Big changes ahead.
AI Summary
On November 19, 2025, Surmodics Inc. announced the termination of a material definitive agreement. The company also reported the completion of an acquisition or disposition of assets, and a notice of delisting or failure to satisfy a continued listing rule. Additionally, there were material modifications to the rights of security holders, changes in control of the registrant, and updates regarding director and officer appointments and compensatory arrangements.
Why It Matters
These events indicate significant strategic shifts and potential restructuring within Surmodics Inc., which could impact its operations, financial performance, and stock value.
Risk Assessment
Risk Level: high — The filing details multiple significant corporate events including termination of agreements, asset disposition, potential delisting, and changes in control, all of which carry substantial risk.
Key Players & Entities
- Surmodics Inc. (company) — Registrant
- November 19, 2025 (date) — Date of earliest event reported
FAQ
What was the material definitive agreement that Surmodics Inc. terminated?
The filing states the termination of a material definitive agreement but does not specify the agreement's name or terms.
What assets were acquired or disposed of by Surmodics Inc.?
The filing confirms the completion of an acquisition or disposition of assets but does not provide details on the specific assets involved.
What is the reason for Surmodics Inc.'s notice of delisting or failure to satisfy a continued listing rule?
The filing indicates a notice of delisting or failure to satisfy a continued listing rule, but the specific reason is not detailed.
What material modifications were made to the rights of Surmodics Inc. security holders?
The filing mentions material modifications to the rights of security holders, but the nature of these modifications is not specified.
Were there any changes in control of Surmodics Inc. reported?
Yes, the filing explicitly states 'Changes in Control of Registrant' as an item of disclosure.
Filing Stats: 2,521 words · 10 min read · ~8 pages · Grade level 11.3 · Accepted 2025-11-19 16:30:15
Key Financial Figures
- $0.05 — ange on which registered Common Stock, $0.05 par value SRDX Nasdaq Global Select
- $43.00 — ere converted into the right to receive $43.00 in cash, without interest (the " Merger
- $25.0 million — Wells Fargo Bank, N.A. with respect to $25.0 million of notional value of the Term Loans fun
Filing Documents
- d864112d8k.htm (8-K) — 51KB
- d864112dex31.htm (EX-3.1) — 6KB
- d864112dex32.htm (EX-3.2) — 46KB
- 0001193125-25-288169.txt ( ) — 237KB
- srdx-20251119.xsd (EX-101.SCH) — 3KB
- srdx-20251119_lab.xml (EX-101.LAB) — 18KB
- srdx-20251119_pre.xml (EX-101.PRE) — 11KB
- d864112d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. d) Exhibits. Exhibit Number Description 2.1* Merger Agreement, dated as of May 28, 2024, by and among Surmodics, Inc., BCE Parent, LLC and BCE Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the SEC on May 29, 2024). 3.1 Amended and Restated Articles of Incorporation of Surmodics, Inc. 3.2 Bylaws of Surmodics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or similar attachment to Exhibit 2.1.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SURMODICS, INC. By: /s/ Robert B. Hance Date: November 19, 2025 Robert B. Hance President, Chief Executive Officer and Assistant Secretary